Unclear behavior monitoring and missed IDT review for psychotropic medications
Summary
The facility failed to define and monitor resident-specific, measurable target behaviors related to Depakote for one resident. The resident’s face sheet listed diagnoses including major depressive disorder, anxiety disorder, psychosis, and dementia, and the H&P noted fluctuating capacity to understand and make decisions. The MDS indicated severe cognitive impairment. The MAR showed an order for Depakote 250 mg twice daily for mood disorder manifested by mood swings, but the RN supervisor stated that mood swings was vague, did not provide a measurable resident-specific indicator for monitoring, and that episodes of mood swings were not monitored in the MAR. The DON also stated that mood swings was vague and did not provide a clear resident-specific parameter for monitoring. The facility also failed to ensure regular IDT conferences were held to assess continued need, justification, and possible gradual dose reduction for psychotropic medications for two residents. One resident had diagnoses including major depressive disorder, anxiety disorder, and unspecified psychosis, with moderately impaired cognition on the MDS. Active orders included duloxetine, gabapentin, buspirone, trazodone, and monitoring for episodes of depression and anxiety each shift. Another resident had a diagnosis of major depressive disorder, intact cognition on the MDS, and active orders for mirtazapine and nortriptyline, along with monitoring for episodes of depression every evening and night shift. During interview and record review, the RN supervisor stated psychiatric behaviors were monitored and documented daily, but no one tallied the behaviors at the end of the month and the IDT did not meet to discuss residents’ behaviors. The DON stated the IDT did not meet to discuss psychiatric behaviors to determine whether treatment needed to be changed or medications altered. The facility policy stated the IDT would review psychotropic medications and that residents would be calendared quarterly thereafter, or with significant change of condition, for IDT review to assess continued need/justification and possible gradual dose reduction.
Penalty
Resources
Below are regulatory guidelines relevant to this citation:
Trusted data from CMS and state health departments
Every citation, penalty and Plan of Correction is sourced from public CMS records (latest release August 26, 2026) and official state health department websites — never guesswork.
In your survey window? See what surveyors are citing.
The Survey-Prep Report maps your facility's risk from 12 months of CMS and state citation data — what's being cited around you and what to check first. $129 one-time.